IS8001A - Bíarýl setin tríasól sem natríum ganga tálmar - Google Patents

Bíarýl setin tríasól sem natríum ganga tálmar

Info

Publication number
IS8001A
IS8001A IS8001A IS8001A IS8001A IS 8001 A IS8001 A IS 8001A IS 8001 A IS8001 A IS 8001A IS 8001 A IS8001 A IS 8001A IS 8001 A IS8001 A IS 8001A
Authority
IS
Iceland
Prior art keywords
baryl
substituted triazole
sodium inhibits
inhibits
sodium
Prior art date
Application number
IS8001A
Other languages
English (en)
Inventor
K. Chakravarty Prasun
H. Fisher Michael
Palucki Brenda
K. Park Min
H. Parsons William
Zhou Bishan
P. Carey James
E. Frantz Douglas
H. Kress Michael
Weaver Damian
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of IS8001A publication Critical patent/IS8001A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8001A 2003-03-18 2005-08-29 Bíarýl setin tríasól sem natríum ganga tálmar IS8001A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18
PCT/US2004/007830 WO2004083190A1 (en) 2003-03-18 2004-03-12 Biaryl substituted triazoles as sodium channel blockers

Publications (1)

Publication Number Publication Date
IS8001A true IS8001A (is) 2005-08-29

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8001A IS8001A (is) 2003-03-18 2005-08-29 Bíarýl setin tríasól sem natríum ganga tálmar

Country Status (34)

Country Link
US (2) US7326726B2 (is)
EP (1) EP1606269B1 (is)
JP (1) JP4482554B2 (is)
KR (1) KR100737721B1 (is)
CN (2) CN1788002A (is)
AR (1) AR044503A1 (is)
AT (1) ATE412639T1 (is)
AU (1) AU2004221885C1 (is)
BR (1) BRPI0408407A (is)
CA (1) CA2519252C (is)
CL (1) CL2004000551A1 (is)
CY (1) CY1108720T1 (is)
DE (1) DE602004017438D1 (is)
DK (1) DK1606269T3 (is)
EC (1) ECSP056018A (is)
EG (1) EG25994A (is)
ES (1) ES2314387T3 (is)
HR (1) HRP20050816A2 (is)
IS (1) IS8001A (is)
JO (1) JO2480B1 (is)
MA (1) MA27665A1 (is)
MX (1) MXPA05009847A (is)
MY (1) MY142651A (is)
NO (1) NO20054775L (is)
NZ (1) NZ542205A (is)
PE (1) PE20041066A1 (is)
PL (1) PL1606269T3 (is)
PT (1) PT1606269E (is)
RU (1) RU2356897C2 (is)
SI (1) SI1606269T1 (is)
TW (1) TWI337605B (is)
UA (1) UA81660C2 (is)
WO (2) WO2004083190A1 (is)
ZA (1) ZA200506906B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303196C1 (en) 2002-12-19 2021-03-25 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
AU2004289694B2 (en) 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
RU2371440C2 (ru) 2004-05-20 2009-10-27 Дзе Скриппс Рисёч Инститьют Стабилизация транстиретина
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
WO2007042250A1 (en) 2005-10-10 2007-04-19 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
CN101641099A (zh) * 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
DK2118077T3 (en) 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 ACTIVITY
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (is) 2011-07-01 2018-04-28
CN103781770B (zh) 2011-09-16 2016-04-13 辉瑞公司 转甲状腺素蛋白解离抑制剂的固体形式
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
SG11202002706XA (en) 2017-10-05 2020-04-29 Biogen Inc Process for preparing alpha-carboxamide pyrolidine derivatives
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US20210002232A1 (en) * 2018-03-09 2021-01-07 Pi Industries Ltd. Heterocyclic compounds as fungicides
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (is) 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
KR20020015308A (ko) 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1390353A1 (en) * 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
RS20050002A (en) * 2002-07-09 2007-09-21 Bristol Myers Squibb Company, Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers

Also Published As

Publication number Publication date
CN101289428A (zh) 2008-10-22
MA27665A1 (fr) 2005-12-01
JP2006520782A (ja) 2006-09-14
CL2004000551A1 (es) 2005-01-21
AU2004221885B2 (en) 2010-04-22
MY142651A (en) 2010-12-15
DK1606269T3 (da) 2009-02-09
SI1606269T1 (sl) 2009-02-28
MXPA05009847A (es) 2005-12-05
TWI337605B (en) 2011-02-21
BRPI0408407A (pt) 2006-03-21
RU2005132168A (ru) 2006-04-27
RU2356897C2 (ru) 2009-05-27
WO2004083189A1 (en) 2004-09-30
WO2004083190A1 (en) 2004-09-30
DE602004017438D1 (de) 2008-12-11
JP4482554B2 (ja) 2010-06-16
ES2314387T3 (es) 2009-03-16
UA81660C2 (ru) 2008-01-25
US7572822B2 (en) 2009-08-11
ATE412639T1 (de) 2008-11-15
PE20041066A1 (es) 2005-01-22
AR044503A1 (es) 2005-09-14
NZ542205A (en) 2008-11-28
CA2519252C (en) 2008-11-18
EP1606269A1 (en) 2005-12-21
HRP20050816A2 (hr) 2006-04-30
AU2004221885C1 (en) 2010-09-23
US7326726B2 (en) 2008-02-05
NO20054775D0 (no) 2005-10-17
EG25994A (en) 2012-11-28
US20050119261A1 (en) 2005-06-02
KR100737721B1 (ko) 2007-07-11
CA2519252A1 (en) 2004-09-30
EP1606269B1 (en) 2008-10-29
US20080171777A1 (en) 2008-07-17
CN1788002A (zh) 2006-06-14
CY1108720T1 (el) 2013-09-04
PL1606269T3 (pl) 2009-04-30
NO20054775L (no) 2005-12-16
PT1606269E (pt) 2008-12-16
KR20050109583A (ko) 2005-11-21
AU2004221885A1 (en) 2004-09-30
ZA200506906B (en) 2007-02-28
TW200505876A (en) 2005-02-16
ECSP056018A (es) 2006-01-27
JO2480B1 (en) 2009-01-20

Similar Documents

Publication Publication Date Title
IS8001A (is) Bíarýl setin tríasól sem natríum ganga tálmar
IS8238A (is) Pýrrólótvíhýdróísókínólín sem PDE10 tálmar
IS8345A (is) 6-útskipt anilínópúrín sem RTK-tálmar
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
IS8384A (is) Alkýleraðar bensímídasólafleiður sem MEK-hindrar
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
IS8492A (is) Setin arýlpýrasól sem snýkladeyðandi miðlar
EP1575487A4 (en) MICROCRYSTALLINE CELLULOSIC COMPOSITIONS
IL176451A0 (en) Novel 2-heteroaryl-substituted benzimidazole derivative
IS7660A (is) Nýjar bensóímídasólafleiður nytsamlegar sem andviðkomumiðlar
DK1569937T3 (da) C-6 modificerede indazolylpyrrolotriaziner
IS8199A (is) Afleiður (þíó) karbamóýl-sýklóhexans sem mótlyf D3/D2 viðtaka
IS8006A (is) Setin pýrimidínón
DK1841758T3 (da) Substituerede triazol-derivater som oxytocin-antagonister
IS7509A (is) Þíoxantínafleiður sem mergperoxídasatálmar
PT1626964E (pt) Novos derivados de benzimidazole
DE60333528D1 (de) Elektrolytzusammensetzungen
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
DK1492934T3 (da) Dørenhed
DE60325848D1 (de) Flammwidrige zusammensetzungen
IS7795A (is) Pyrrólafleiður sem efnasambönd gegn sveppagerlum
IS7957A (is) Tríasól efnasambönd sem eru gagnleg við meðferð
ATE342335T1 (de) Bleichmittelzusammensetzungen
ZA200508151B (en) Benzimidazole-derivatives as factor Xa inhibitors
DE502004006272D1 (de) Schutzschalter